ScripThe CEO of Arvinas has admitted that Pfizer could seek to renegotiate or even walk away from their partnership to market vepdegestrant, just as the companies submit the protein degrader breast cancer
ScripEarly data on Ichnos Glenmark Innovation’s (IGI) trispecific T-cell engager ISB 2001 in multiple myeloma presented at the American Society of Clinical Oncology (ASCO) meeting has signalled “deep and d
ScripData presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech